KIT and systemic mastocytosis: Due to the rarity of these SM cases lacking exon 17 KIT mutations (≤ 4%) [6], a critical review of mastocytosis cases treated with imatinib who have been reported in the literature is also provided to better estimate the response rates to imatinib according to the KIT mutational status.